Progenics Pharmaceuticals (PGNX) Posts Narrower than Expected Q3 Loss
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) reported Q3 loss of ($0.34), $0.01 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $6.5 million.